-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx joins France’s DETECSEPS clinical study using Nu.Q NETs biomarker for early sepsis detection

PUBT·09/17/2026 12:17:53
Listen to the news
VolitionRx joins France’s DETECSEPS clinical study using Nu.Q NETs biomarker for early sepsis detection
  • VolitionRx launched the DETECSEPS program in France to evaluate early sepsis detection using its Nu.Q NETs blood biomarker.
  • No clinical results have been presented; the project will generate real-world evidence on emergency-department triage for suspected infections.
  • The French government-backed consortium is funded at EUR 6.3 million, positioning the test for potential broader clinical adoption if validated.
  • IDS France will supply the IDS i10 automated analyzer to run the assay, supporting rapid hospital workflow integration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: FR50557) on September 17, 2026, and is solely responsible for the information contained therein.